Core Viewpoint - PharmaTher Holdings Ltd. is advancing its ketamine program for treating levodopa-induced dyskinesia (LID-PD) in Parkinson's disease patients, aiming for a Phase 3 clinical study to support a New Drug Application (NDA) [1][2][16] Development Strategy - The company is utilizing the 505(b)(2) regulatory pathway to leverage existing scientific evidence and FDA-reviewed Chemistry, Manufacturing and Controls (CMC) to minimize development risks, costs, and timelines [2][6] - A Phase 3 clinical study is being prepared to evaluate the efficacy and safety of ketamine for LID-PD, pending FDA feedback [2][10] Mechanism and Clinical Evidence - Ketamine's mechanism as a non-competitive NMDA receptor antagonist provides a strong biological rationale for its evaluation in LID-PD, given the involvement of excessive glutamatergic/NMDA signaling in dyskinesia [4] - Previous Phase I/II studies indicated that ketamine was safe and well-tolerated, with significant reductions in dyskinesias observed: 51% reduction during Infusion 2, 49% at 3 weeks, and 41% at 3 months [5] Market Opportunity - The U.S. market opportunity for a ketamine-based treatment in LID-PD is estimated between $0.75 billion and $2.2 billion, based on the prevalence of dyskinesia among Parkinson's patients [12] - Approximately 1.1 million individuals in the U.S. have Parkinson's disease, with 30-40% developing dyskinesia, leading to a potential treated population of 330,000 to 440,000 [11][12] Strategic Significance - The LID-PD program represents a high-value opportunity in a validated treatment category, supported by proprietary clinical data and patent protection until 2036 [13] - The company is engaged in discussions with potential pharmaceutical partners to enhance capital efficiency and advance the program [10][13] Upcoming Catalysts - Key upcoming milestones include a Pre-Phase 3 FDA meeting, finalization of the pivotal study protocol, and initiation of the late-stage study contingent on FDA alignment and financing [19]